Irinotesin (Irinotecan Hydrochloride Trihydrate)

Irinotecan is converted inside cells to the metabolite SN‑38, which binds to the DNA‑topoisomerase I complex and prevents the re‑ligation of DNA strands during replication. This leads to accumulation of DNA breaks, triggering apoptosis of rapidly dividing cancer cells while sparing most normal tissues.

The dosing regimen for Irinotesin is determined by the prescribing oncologist based on the patient’s clinical condition, body surface area, and treatment protocol. Dosage adjustments may be required for renal or hepatic impairment, and the prescriber will set the appropriate schedule.

Irinotecan is classified as a pregnancy‑category unknown drug. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment and for a defined period afterward.

To request Irinotesin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Irinotecan is a widely used topoisomerase I inhibitor with a well‑characterized efficacy profile in colorectal cancer. Compared with other agents in the same class, such as topotecan, irinotecan has a distinct toxicity spectrum, notably a higher incidence of severe diarrhea, while topotecan is more associated with hematologic toxicity. Choice of therapy depends on tumor type, prior treatment, and patient tolerance.

Irinotesin should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. Once prepared for infusion, use the solution within the time frame specified by the manufacturer and follow aseptic techniques.

Irinotesin is supplied as an injectable solution for intravenous infusion. It is administered by a qualified healthcare professional, typically over a period of 30 to 90 minutes, depending on the prescribed protocol. Infusion rates and pre‑medication (e.g., anti‑emetics) are determined by the treating physician.

The most serious risks of Irinotesin include severe neutropenia leading to infection, febrile neutropenia, life‑threatening diarrhea or colitis, hepatic toxicity, and rare hypersensitivity reactions such as anaphylaxis. Patients should be monitored closely for signs of infection, gastrointestinal distress, and liver function abnormalities throughout treatment.

Irinotesin is contraindicated in patients with known hypersensitivity to irinotecan or any of its excipients. It should be used with caution in individuals with significant bone‑marrow suppression, severe hepatic impairment, or uncontrolled infections. Pregnant or breastfeeding women should only use the drug when the potential benefits outweigh the risks.